In-Office Procedures · Diagnostic
Dry Eye Testing and Diagnostics
Dry eye is confirmed with a panel of objective markers, not a single test. The goal is to prove disease, identify the subtype, grade severity, and set a baseline you can follow over time.
Key points
- No single test defines dry eye; a short panel of homeostasis markers does.
- Osmolarity grades tear instability and severity with one objective number.
- Point-of-care MMP-9 flags clinically meaningful ocular surface inflammation.
- Meibography and tear imaging reveal the evaporative, MGD-driven component.
Why a panel, not one test
Dry eye is multifactorial, so the modern approach pairs a validated symptom questionnaire with objective signs. A patient can report high symptoms with a near-normal surface, or few symptoms with significant staining. Running the same short battery each visit is what separates evaporative from aqueous-deficient disease and tells you what to treat first.
The core markers
Tear osmolarity gives one objective number: a reading at or above about 308 mOsm per liter in either eye, or an inter-eye difference greater than about 8 mOsm per liter, supports the diagnosis and reflects tear instability. A positive point-of-care MMP-9 test indicates inflammation above the assay threshold, about 40 ng per mL, which supports anti-inflammatory therapy. Non-invasive tear breakup time and ocular surface staining show how quickly the film fails and where the surface is damaged, and meibography images the glands so you can grade dropout.
How the markers fit together
The TFOS DEWS III diagnostic framework confirms dry eye when a positive symptom score is paired with at least one objective homeostasis marker: reduced tear breakup time, raised or unstable osmolarity, or ocular surface staining. Once disease is confirmed, subtyping markers such as meibography and tear volume point you toward the evaporative or aqueous-deficient pathway that should drive treatment.
Clinical evidence
- TFOS DEWS III Diagnostic Methodology (2025) supports a symptom score plus homeostasis markers (tear breakup time, osmolarity, staining) as the basis of diagnosis. American Journal of Ophthalmology
Available on Dry Eye Rescue
Osmolarity systems and test cards, MMP-9 kits, meibography-capable imaging, vital dyes, and the consumables that go with them are on the wholesale platform. Most practices start with osmolarity and MMP-9, then add imaging as dry eye volume grows.
Sources are linked inline above. Device descriptions reference FDA clearance status, published peer-reviewed studies, and manufacturer data. Clinical outcomes are not a guarantee of individual results. Review full prescribing information, the IFU, and FDA clearance documentation for each device before use.
